We are analyzing https://link.springer.com/article/10.1007/s00059-004-2556-6.

Title:
Rapamycin Analogs for Stent-Based Local Drug Delivery | Herz
Description:
The inhibitory action of the sirolimus-like agent everolimus on smooth muscle cell proliferation, evidenced in animal models, has triggered the interest in everolimus as stent coating for local inhibition of in-stent restenosis. For preclinical and clinical evaluation of safety and efficacy of an everolimus-eluting stent design, a new stent has recently been introduced by Biosensors International Inc, covered by a resorbable “composite” coating, that contains the immunosuppressive drug within a polyhydroxyacid biodegradable polymer matrix with roughly equal resorption rates. FUTURE I, the feasibility trial of this new stent concept, revealed a 30-day MACE (major adverse cardiac events) rate of 0% as well as a restenosis rate of 0% at 6-month follow-up in a total of 32 patients included. The more sensitive QCA (quantitative computerized analysis) and IVUS (intravascular ultrasound) parameters showed an 88% reduction of in-stent late loss and an 87% reduction of the neointimal volume. Adding a second feasibility trial including diabetics, the multicenter trial FUTURE II confirmed the initial beneficial findings of FUTURE I in a total of 64 patients in a 1 : 2 randomization to a bare metal control stent. Based on these results, the FUTURE program has now been expanded by Guidant with two large-scale multicenter studies, FUTURE III and IV, which evaluate this stent design in a larger patient population. Furthermore, FUTURE IV is addressed to demonstrate the non-inferiority of this stent concept in a head-to-head comparison to an approved drug-eluting stent (DES) concept. In contrast to everolimus, tacrolimus is a well-known potent antiproliferative agent, already used in various therapeutic areas. Preclinical studies on tacrolimus-eluting stents for treatment of native coronary artery lesions demonstrated safety and efficacy of this stent concept with significant reduction of neointimal proliferation within the implanted study stents. However, the clinical trial program of the first tacrolimus-eluting stent system in the treatment of native coronary lesions (PRESENT I, II) and saphenous vein graft lesions (EVIDENT) failed to prove the clinical benefit of the stent systems tested and demonstrated the impact of specific stent designs, especially the drug carrier characteristics, on the patient outcome. The progressive PRESET study, evaluating a directly coated tacrolimus-eluting stent, will provide important insights, that will clarify the potential of tacrolimus for prevention of neointimal proliferation in clinical practice without being affected by any additional artificial surface compounds.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Insurance
Technology & Computing
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,603,474 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

stent, article, everolimus, future, drug, stents, tacrolimus, tacrolimuseluting, privacy, cookies, content, grube, coronary, publish, search, eberhard, restenosis, clinical, efficacy, trial, concept, artery, koronarstents, stentdesigns, access, data, information, log, journal, research, herz, local, buellesfeld, proliferation, coating, instent, evaluation, safety, month, reduction, neointimal, lesions, rahmen, nun, behandlung, discover, author, siegburg, springer, optional,

Topics {✒️}

tacrolimus-eluting stent system approved drug-eluting stent everolimus-eluting stent design eberhard grube md related subjects stent late loss tacrolimus-eluting stents month download article/chapter native coronary lesions future iv tacrolimus-eluting stent everolimus-eluting stent large-scale multicenter studies progressive preset study future iii durch biosensors int resorbable “composite” coating quantitative computerized analysis potent antiproliferative agent der vergangenheit sowie von bypassläsionen article herz aims implanted study stents full article pdf stent coating local inhibition drug carrier characteristics arterial drug retention privacy choices/manage cookies welches potential tacrolimus article grube stent systems tested specific stent designs rapamycin analogs stent restenosis iv future program clinical benefit european economic area initial beneficial findings des provide important insights conditions privacy policy larger patient population heart center siegburg safety evaluation clinical trial program accepting optional cookies agent everolimus guidant

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Rapamycin Analogs for Stent-Based Local Drug Delivery
         description:The inhibitory action of the sirolimus-like agent everolimus on smooth muscle cell proliferation, evidenced in animal models, has triggered the interest in everolimus as stent coating for local inhibition of in-stent restenosis. For preclinical and clinical evaluation of safety and efficacy of an everolimus-eluting stent design, a new stent has recently been introduced by Biosensors International Inc, covered by a resorbable “composite” coating, that contains the immunosuppressive drug within a polyhydroxyacid biodegradable polymer matrix with roughly equal resorption rates. FUTURE I, the feasibility trial of this new stent concept, revealed a 30-day MACE (major adverse cardiac events) rate of 0% as well as a restenosis rate of 0% at 6-month follow-up in a total of 32 patients included. The more sensitive QCA (quantitative computerized analysis) and IVUS (intravascular ultrasound) parameters showed an 88% reduction of in-stent late loss and an 87% reduction of the neointimal volume. Adding a second feasibility trial including diabetics, the multicenter trial FUTURE II confirmed the initial beneficial findings of FUTURE I in a total of 64 patients in a 1 : 2 randomization to a bare metal control stent. Based on these results, the FUTURE program has now been expanded by Guidant with two large-scale multicenter studies, FUTURE III and IV, which evaluate this stent design in a larger patient population. Furthermore, FUTURE IV is addressed to demonstrate the non-inferiority of this stent concept in a head-to-head comparison to an approved drug-eluting stent (DES) concept. In contrast to everolimus, tacrolimus is a well-known potent antiproliferative agent, already used in various therapeutic areas. Preclinical studies on tacrolimus-eluting stents for treatment of native coronary artery lesions demonstrated safety and efficacy of this stent concept with significant reduction of neointimal proliferation within the implanted study stents. However, the clinical trial program of the first tacrolimus-eluting stent system in the treatment of native coronary lesions (PRESENT I, II) and saphenous vein graft lesions (EVIDENT) failed to prove the clinical benefit of the stent systems tested and demonstrated the impact of specific stent designs, especially the drug carrier characteristics, on the patient outcome. The progressive PRESET study, evaluating a directly coated tacrolimus-eluting stent, will provide important insights, that will clarify the potential of tacrolimus for prevention of neointimal proliferation in clinical practice without being affected by any additional artificial surface compounds.
         datePublished:
         dateModified:
         pageStart:162
         pageEnd:166
         sameAs:https://doi.org/10.1007/s00059-004-2556-6
         keywords:
            Drug eluting stents
            Coronary artery disease
            New device
            Everolimus
            Tacrolimus
            Medikamentenbeschichtete Stents
            Koronare Herzkrankheit
            Neue Technologie
            Everolismus
            Cardiology
            Internal Medicine
         image:
         isPartOf:
            name:Herz
            issn:
               1615-6692
               0340-9937
            volumeNumber:29
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Urban & Vogel
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Eberhard Grube
               affiliation:
                     name:Heart Center Siegburg
                     address:
                        name:Department of Cardiology/Angiology, Heart Center Siegburg, Germany
                        type:PostalAddress
                     type:Organization
                     name:Heart Center Siegburg
                     address:
                        name:Department of Cardiology/Angiology, Heart Center Siegburg, Siegburg, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Lutz Buellesfeld
               affiliation:
                     name:Heart Center Siegburg
                     address:
                        name:Department of Cardiology/Angiology, Heart Center Siegburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Rapamycin Analogs for Stent-Based Local Drug Delivery
      description:The inhibitory action of the sirolimus-like agent everolimus on smooth muscle cell proliferation, evidenced in animal models, has triggered the interest in everolimus as stent coating for local inhibition of in-stent restenosis. For preclinical and clinical evaluation of safety and efficacy of an everolimus-eluting stent design, a new stent has recently been introduced by Biosensors International Inc, covered by a resorbable “composite” coating, that contains the immunosuppressive drug within a polyhydroxyacid biodegradable polymer matrix with roughly equal resorption rates. FUTURE I, the feasibility trial of this new stent concept, revealed a 30-day MACE (major adverse cardiac events) rate of 0% as well as a restenosis rate of 0% at 6-month follow-up in a total of 32 patients included. The more sensitive QCA (quantitative computerized analysis) and IVUS (intravascular ultrasound) parameters showed an 88% reduction of in-stent late loss and an 87% reduction of the neointimal volume. Adding a second feasibility trial including diabetics, the multicenter trial FUTURE II confirmed the initial beneficial findings of FUTURE I in a total of 64 patients in a 1 : 2 randomization to a bare metal control stent. Based on these results, the FUTURE program has now been expanded by Guidant with two large-scale multicenter studies, FUTURE III and IV, which evaluate this stent design in a larger patient population. Furthermore, FUTURE IV is addressed to demonstrate the non-inferiority of this stent concept in a head-to-head comparison to an approved drug-eluting stent (DES) concept. In contrast to everolimus, tacrolimus is a well-known potent antiproliferative agent, already used in various therapeutic areas. Preclinical studies on tacrolimus-eluting stents for treatment of native coronary artery lesions demonstrated safety and efficacy of this stent concept with significant reduction of neointimal proliferation within the implanted study stents. However, the clinical trial program of the first tacrolimus-eluting stent system in the treatment of native coronary lesions (PRESENT I, II) and saphenous vein graft lesions (EVIDENT) failed to prove the clinical benefit of the stent systems tested and demonstrated the impact of specific stent designs, especially the drug carrier characteristics, on the patient outcome. The progressive PRESET study, evaluating a directly coated tacrolimus-eluting stent, will provide important insights, that will clarify the potential of tacrolimus for prevention of neointimal proliferation in clinical practice without being affected by any additional artificial surface compounds.
      datePublished:
      dateModified:
      pageStart:162
      pageEnd:166
      sameAs:https://doi.org/10.1007/s00059-004-2556-6
      keywords:
         Drug eluting stents
         Coronary artery disease
         New device
         Everolimus
         Tacrolimus
         Medikamentenbeschichtete Stents
         Koronare Herzkrankheit
         Neue Technologie
         Everolismus
         Cardiology
         Internal Medicine
      image:
      isPartOf:
         name:Herz
         issn:
            1615-6692
            0340-9937
         volumeNumber:29
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Urban & Vogel
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Eberhard Grube
            affiliation:
                  name:Heart Center Siegburg
                  address:
                     name:Department of Cardiology/Angiology, Heart Center Siegburg, Germany
                     type:PostalAddress
                  type:Organization
                  name:Heart Center Siegburg
                  address:
                     name:Department of Cardiology/Angiology, Heart Center Siegburg, Siegburg, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Lutz Buellesfeld
            affiliation:
                  name:Heart Center Siegburg
                  address:
                     name:Department of Cardiology/Angiology, Heart Center Siegburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Herz
      issn:
         1615-6692
         0340-9937
      volumeNumber:29
Organization:
      name:Urban & Vogel
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Heart Center Siegburg
      address:
         name:Department of Cardiology/Angiology, Heart Center Siegburg, Germany
         type:PostalAddress
      name:Heart Center Siegburg
      address:
         name:Department of Cardiology/Angiology, Heart Center Siegburg, Siegburg, Germany
         type:PostalAddress
      name:Heart Center Siegburg
      address:
         name:Department of Cardiology/Angiology, Heart Center Siegburg, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Eberhard Grube
      affiliation:
            name:Heart Center Siegburg
            address:
               name:Department of Cardiology/Angiology, Heart Center Siegburg, Germany
               type:PostalAddress
            type:Organization
            name:Heart Center Siegburg
            address:
               name:Department of Cardiology/Angiology, Heart Center Siegburg, Siegburg, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Lutz Buellesfeld
      affiliation:
            name:Heart Center Siegburg
            address:
               name:Department of Cardiology/Angiology, Heart Center Siegburg, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Cardiology/Angiology, Heart Center Siegburg, Germany
      name:Department of Cardiology/Angiology, Heart Center Siegburg, Siegburg, Germany
      name:Department of Cardiology/Angiology, Heart Center Siegburg, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(27)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.54s.

LINK . SPRINGER . COM {}